Celltrion, Inc. et al. vs. Regeneron Pharmaceuticals, Inc.
Explore the PTAB proceeding IPR2023-00462 filed by Celltrion, Inc. et al. on 2023-01-17. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2023-00462
Filing Date
2023-01-17
Accorded Filing Date
2023-01-17
Institution Decision Date
2023-07-20
Last Modified Date
2024-05-24
Proceeding Type
IPR
Termination Date
2024-02-21
Trial Status
Terminated-Adverse Judgment
Parties & Counsel
Petitioner
Celltrion, Inc. et al.
Represented By
Green, Loraet alPatent Owner / Respondent
Regeneron Pharmaceuticals, Inc.
Represented By
Brausa, Adamet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
2 Total
Proceeding Status
Terminated-Adverse Judgment
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (2)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 41408 | David Marsh | +1 202-942-5068 |
| 48001 | Thomas Triolo | +1 914-847-1612 |
| 48921 | Stephen Gaudet | +1 914-847-7376 |
| 50370 | Neil Miyamoto | +1 914-847-7175 |
| 50437 | Frank Cottingham | +1 914-593-1116 |
| 58583 | Brian Cocca | +1 914-847-1421 |
| 58714 | Ilona Gont | +1 914-847-1304 |
| 59668 | Brandon Schurter | +1 914-847-7000 |
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 16 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 10,464,992 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,066,458 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,084,865 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,732,024 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2023037410 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,331,099 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2025025711 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 81,448,406 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,608,261 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 7,807,164 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,092,803 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,481,046 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,802,107 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,340,594 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,914,763 B2 | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi SwissBioSim GmbH et al. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. v. Regeneron Pharmaceuticals, Inc.
Formycon AG v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. REGENERON PHARMACEUTICALS, INC.
Chengdu Kanghong Biotechnology Co., Ltd. et al. v. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc.
Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, CO., LTD.